Canlitinib
Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2) . Canlitinib has the potential for cancer study.
Product Specifications
CAS Number
[2222730-78-9]
UNSPSC
12352005
Target
C-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/canlitinib.html
Purity
97.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(CCCCCOC1=CC2=NC=CC(OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(C=C5)F)=O)=O)C=C3F)=C2C=C1OC)O
Molecular Formula
C33H31F2N3O7
Molecular Weight
619.61
References & Citations
[1]Zhang, Zhiqiang, et al. Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof. WO2017-CN104518
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
